Jose R. Alamo

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Foamy cell infiltration as a morphological challenge: Histiocytosis versus plasma cell neoplasm.

Foamy cell infiltration as a morphological challenge: Histiocytosis versus plasma cell neoplasm.

Journal: British journal of haematology
Published: June 04, 2026

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Journal: HemaSphere
Published: December 28, 2025

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Journal: Experimental hematology & oncology
Published: December 26, 2024

A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.

A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.

Journal: Leukemia
Published: November 18, 2024

Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.

Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.

Journal: British journal of haematology
Published: September 18, 2024

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Journal: International journal of molecular sciences
Published: June 17, 2024

The genomic landscape of transformed splenic diffuse red pulp small B-cell lymphoma.

The genomic landscape of transformed splenic diffuse red pulp small B-cell lymphoma.

Journal: EJHaem
Published: June 11, 2024

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Journal: Blood advances
Published: May 14, 2024

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.

Journal: Blood neoplasia
Published: May 06, 2024

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Journal: The oncologist
Published: December 09, 2023

Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.

Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.

Journal: Annals of hematology
Published: November 20, 2023

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.

Journal: British journal of haematology
Published: August 10, 2023
Showing 1-12 of 15

Last Updated: 09/26/2026